Skip to Content
Merck
  • Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope.

Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope.

NPJ vaccines (2021-10-27)
Morgan E Abernathy, Harry B Gristick, Jost Vielmetter, Jennifer R Keeffe, Priyanthi N P Gnanapragasam, Yu E Lee, Amelia Escolano, Rajeev Gautam, Michael S Seaman, Malcolm A Martin, Michel C Nussenzweig, Pamela J Bjorkman
ABSTRACT

HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies against a desired epitope, while eliminating responses to off-target regions of HIV-1 Env. We report characterization of Ab1245, an off-target antibody against the Env gp120-gp41 interface, from V3-glycan patch immunogen-primed and boosted macaques. A 3.7 Å cryo-EM structure of an Ab1245-Env complex reveals one Ab1245 Fab binding asymmetrically to Env trimer at the gp120-gp41 interface using its long CDRH3 to mimic regions of gp41. The mimicry includes positioning of a CDRH3 methionine into the gp41 tryptophan clasp, resulting in displacement of the fusion peptide and fusion peptide-proximal region. Despite fusion peptide displacement, Ab1245 is non-neutralizing even at high concentrations, raising the possibility that only two fusion peptides per trimer are required for viral-host membrane fusion. These structural analyses facilitate immunogen design to prevent elicitation of Ab1245-like antibodies that block neutralizing antibodies against the fusion peptide.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thyroglobulin from bovine thyroid, (For Gel Filtration Chromatography)